Document Detail


Efficacy of preoperative albendazole use according to months in hydatid cyst of the liver.
MedLine Citation:
PMID:  17426473     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE: Hydatid cyst is still a significant health and economical problem due to insufficient preventive measures. Infestation by hydatid disease in humans most commonly occurs in the liver and causes complications unless treated properly. Therefore, hepatic hydatid cyst should immediately be treated when diagnosed. Today, the treatment of hydatid cysts is principally surgical. To avoid recurrence, viable scoleces in the hydatid cyst should be eliminated before emptying surgically. Length of Albendazole therapy, a drug effective on scoleces in the cyst, is still controversial. METHODS: In this study, there was a significant difference in the rate of viable scoleces when group III receiving albendazole for 3 months preoperatively was compared with group I, group II, and the control group. We do think 3-month preoperative abendazole treatment is effective in reducing the rate of recurrence and if still viable scoleces are observed in the surgery, albendazole treatment should be continued for 1 month postoperatively. RESULTS: After the therapy, in group I 10 (47.6%), in group II 7 (33.3%), and in group III 2 (0.9%) patient's scoleces were alive. In the control group (group IV) 17 (80%) patients' scoleces were intact. When group III is compared with the control group, a significant difference was observed (P<0.05). Yet again, there was a significant difference between the groups when groups I and II were compared with group III. CONCLUSIONS: We concluded that in treatment of hydatid cyst, albendazole should be continued at least for 3 months preoperatively and if still viable scoleces are identified, medical treatment should follow the surgical intervention at least for 1 month to decrease the possibility of residual cysts and recurrence.
Authors:
Nejdet Bildik; Ayhan Cevik; Mehmet Altintaş; Hüseyin Ekinci; Mustafa Canberk; Mustafa Gülmen
Related Documents :
1458013 - Growth hormone therapy in turner's syndrome: an update on final height. genentech natio...
1394033 - Association of aneuploidy in index adenomas with metachronous colorectal adenoma develo...
20947673 - Cross-cultural differences in knee functional status outcomes in a polyglot society rep...
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Journal of clinical gastroenterology     Volume:  41     ISSN:  0192-0790     ISO Abbreviation:  J. Clin. Gastroenterol.     Publication Date:  2007 Mar 
Date Detail:
Created Date:  2007-04-11     Completed Date:  2007-06-14     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7910017     Medline TA:  J Clin Gastroenterol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  312-6     Citation Subset:  IM    
Affiliation:
Dr Lütfi Kirdar Kartal Training and Research Hospital, 2nd General Surgery Clinic, Kartal, 34865 Istanbul, Turkey.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Aged
Albendazole / administration & dosage,  therapeutic use*
Animals
Anticestodal Agents / administration & dosage,  therapeutic use*
Echinococcosis, Hepatic / drug therapy*,  pathology,  surgery
Echinococcus granulosus / drug effects
Female
Humans
Male
Middle Aged
Prospective Studies
Time Factors
Treatment Outcome
Turkey
Chemical
Reg. No./Substance:
0/Anticestodal Agents; 54965-21-8/Albendazole

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Factors associated with abnormal gastric emptying in alcohol-related chronic pancreatitis.
Next Document:  The clinical characteristics of rhabdomyolysis in patients with liver cirrhosis.